Hematopoietic Gene Therapies for Metabolic and Neurologic Diseases

Publication date: Available online 23 July 2017
Source:Hematology/Oncology Clinics of North America
Author(s): Alessandra Biffi

Teaser

Increasingly, patients affected by metabolic diseases affecting the central nervous system and neuroinflammatory disorders receive hematopoietic cell transplantation (HCT) in the attempt to slow the course of their disease, delay or attenuate symptoms, and improve pathologic findings. The possible replacement of brain-resident myeloid cells by the transplanted cell progeny contributes to clinical benefit. Genetic engineering of the cells to be transplanted (hematopoietic stem cell) may endow the brain myeloid progeny of these cells with enhanced or novel functions, contributing to therapeutic effects.


http://ift.tt/2trondE